Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Core Points - Evogene Ltd. has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum bid price of $1.00 for 10 consecutive business days [1][2] - The compliance issue regarding the bid price deficiency is now considered closed by Nasdaq [2] Company Overview - Evogene Ltd. is a computational biology company that utilizes big data and artificial intelligence to enhance the development of life-science products, aiming to increase success rates while reducing time and costs [3] - The company has established three unique tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focusing on different core components such as microbes, small molecules, and genetic elements [4] - Evogene operates through five subsidiaries, including Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd., which are involved in developing microbiome-based therapeutics, ag-biologicals, next-generation ag chemicals, and superior castor seed varieties respectively [4]